NCT06224192: An ongoing trial by Amgen
This trial is ongoing. It must report results 3 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06224192 |
|---|---|
| Title | A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 2, 2024 |
| Completion date | April 11, 2025 |
| Required reporting date | April 11, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |